Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic is expected to be a strong long-term investment, with a buy rating and updated price target of $22 per share. This optimistic outlook is based on an equally weighted composite of a 20x multiple of taxed and diluted 2036 EPS and an NPV discounted cash flow between 2026-2036, which together reflect the expected P/E multiple and discount rates of a developmental stage biopharmaceutical company. While risks include potential failure in the developmental candidates to meet peak commercial revenue projections and challenges in securing sufficient capital resources, the recent oversubscribed private placement indicates confidence in Immunic's future potential as it transitions into a commercial-stage multiple sclerosis company.

Immunic is facing technical pressure from a potential reverse split and follow-on financing, leading to a negative outlook as these factors may overshadow potential catalysts such as the Phase 3 ENSURE data readout and progression in the PPMS program. Additionally, the company's focus on targeting multiple disease modifying factors may be a strategic pivot, but it also introduces a higher level of clinical and commercial risk. Finally, leadership changes and the need for a CEO with deep commercial multiple sclerosis expertise may also be a concern for the company's future success.